# TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) · Edgar & Edgarette company card

> Tonix Pharmaceuticals Holding (TNXP) grew revenue 29.8% in FY2025 to $13 million, operating margin -959% against a -3.8% median for pharmaceutical preparations, equity 88.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1430306 · fiscal year ended 2025-12-31 · 3 audited years read · [page](https://www.pops4.com/boards/company/TNXP) · [JSON](https://www.pops4.com/boards/company/TNXP.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $13M |
| Revenue growth, 1 year | 29.8% |
| Revenue growth per year | 29.9% |
| Operating margin | -959.1% (prior year -1354.3%) |
| Net margin | -946.2% |
| Operating cash flow | −$100M |
| Capital spending | $3M |
| Free cash flow | −$103M |
| Cash | $208M |
| Long-term debt | — |
| Total assets | $277M |
| Total equity | $245M |
| Equity ÷ assets | 88.4% |
| Return on equity | -50.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -0.37 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -2.42 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed auditor change in the last 12 months; operating cash flow was negative; operating loss: a margin of -959.1% in FY2025; revenue is hard to predict: its 80% range is ±28%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $13.1M (FY2025). Experience: revenue up 29.8% on the year, up 29.9% a year over 2 years; operating margin -959.1%, up from -1354.3%. Soundness: equity 88.4% of assets, return on equity -50.6%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $12.5M and $22.4M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -959.1% against a -3.8% median; growth 29.8% against 13.7%.

Range logged 2026-09-20, receipt d37d11cc86cfb6ae, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 4.01 Auditor change: 1, latest 2026-03-18 ([filing](https://www.sec.gov/Archives/edgar/data/1430306/000199937126006169/0001999371-26-006169-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-08-18 ([filing](https://www.sec.gov/Archives/edgar/data/1430306/000149315226039000/0001493152-26-039000-index.htm))

## Recent filings

- 8-K · filed 2026-10-15 · 2.02 Results of Operations and Financial Condition; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1430306/000149315226047139/0001493152-26-047139-index.htm)
- 8-K · filed 2026-10-02 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1430306/000149315226045603/0001493152-26-045603-index.htm)
- 8-K · filed 2026-09-22 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1430306/000149315226043644/0001493152-26-043644-index.htm)
- 8-K · filed 2026-09-08 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1430306/000149315226041689/0001493152-26-041689-index.htm)
- 8-K · filed 2026-08-18 · 5.02 Departure or Election of Directors; Appointment of Officers; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1430306/000149315226039000/0001493152-26-039000-index.htm)
- 10-Q · filed 2026-08-10 · [filing](https://www.sec.gov/Archives/edgar/data/1430306/000199937126017452/0001999371-26-017452-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001430306.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1430306

## Cite

POPS4, Edgar & Edgarette: TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/TNXP. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.